Gilead Sciences (NASDAQ:GILD) Posts Earnings Results, Beats Estimates By $0.23 EPS

Gilead Sciences (NASDAQ:GILD) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23, Zacks reports. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences updated its FY 2025 guidance to 7.700-8.100 EPS.

Gilead Sciences Stock Up 0.7 %

NASDAQ GILD opened at $96.14 on Wednesday. The stock’s 50 day simple moving average is $93.07 and its 200 day simple moving average is $86.99. Gilead Sciences has a one year low of $62.07 and a one year high of $100.51. The firm has a market cap of $119.82 billion, a PE ratio of 1,068.22, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Analysts Set New Price Targets

A number of research analysts have recently commented on GILD shares. Citigroup initiated coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Oppenheimer upped their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Piper Sandler boosted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. BMO Capital Markets upped their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Barclays lifted their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $98.83.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 572,824 shares of company stock worth $53,611,715. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.